4th Annual Congress

Programme and Abstracts

2–4 February 2011

Starling Geneva Hotel & Conference Center,
Geneva, Switzerland
European Association for Haemophilia and Allied Disorders
4th Annual Congress, Wednesday 2nd – Friday 4th February 2011 Geneva

EAHAD Executive Committee

PM. Mannucci
J. Astermak
Ph. de Moerloose
G. Dolan
Ch. Ludlam
K. Fischer
C. Harrington
M. Makris
Cl. Negrier
J. Oldenburg
I. Peake

President
Vice-President
Secretary
Company Secretary
Past President

European Association for Haemophilia and Allied Disorders Ltd
Limited Company registered in England No. 06373427
Registered as a Charity in England No. 1125081

EAHAD Secretariat,
City View Hose Union Street,
Manchester, M12 4JD, UK
Financial assistance is gratefully acknowledged from

Baxter Healthcare SA
Bayer Schering Pharma
bioMérieux Suisse SA
CSL Behring
GlaxoSmithKline
Hyphen BioMed / Endotell
Inspiration Biopharmaceuticals
Instrumentation Laboratory
LFB
Novo Nordisk
Octapharma AG
Pfizer Specialty Care Europe
Roche Diagnostics
Stago
Swedish Orphan Biovitrum/Biogen Idec Hemophilia
SYMPOSIA

WEDNESDAY 2nd February, 2011

Registration Opening Times  13:00–19:00 (level -1 of the Hotel)
All sessions take place in the plenary room Crans-Montana, level -1 of the Hotel

14:30–16:00
Swedish Orphan Biovitrum/Biogen Idec Hemophilia Satellite Symposium

Fc Technology in Hemophilia: An approach to prolonged protection
Chairman: Professor Erik Berntorp (Sweden), Co-Chairman: Dr Stephen James (Sweden)

The Technology
14:30–14:40 Long-acting factor concentrates: Technical possibilities, Professor Erik Berntorp (Sweden)
14:40–14:50 Fc fusion technology: Molecular and preclinical studies, Dr Glenn Pierce (US)
14:50–15:00 Question and Panel Discussion

The Clinical Program
15:00–15:15 rFIXFc Phase I/IIa data and B-LONG Clinical Trial, Professor K. John Pasi (UK)
15:15–15:30 rFVIIIFc Phase I/IIa data and A-LONG Clinical Trial, Associate Professor Neil C. Josephson (US)
15:30–15:40 Regulatory authority guidelines for clinical documentation of FVIII and FIX, Jørgen Ingerslev (Denmark)
15:40–16:00 Question and Panel Discussion

WEDNESDAY 2nd February, 2011

16:30–18:00
Bayer Schering Pharma Satellite Symposium

The Future Outlook in Hemophilia
Chairman: Johannes Oldenburg (Germany)

16.30–16.35 Welcome
J. Oldenburg

E. Santagostino (Italy)

16.55–17.15 New Patient Care Opportunities Through Innovative Research
J. Mahlangu (South Africa)

17.15–17.35 Socioeconomic Aspects of Management: The Case for Additional Support
K. Steen Carlsson (Sweden)
K. Berger (Germany)

17.35–17.50 Debating the Balance Between Components of Care
Moderated by J. Oldenburg

17.50–18.00 Discussion and Close
J. Oldenburg
WEDNESDAY 2nd February, 2011
18:30–20:00
Pfizer Satellite Symposium
Managing Haemophilia for Life “Beta, gamma, delta”- Transitions in childhood and adolescence towards adulthood
Chairmen: Pier Mannuccio Mannucci (Italy), Jan Astermark (Sweden)

Welcome and introduction
The challenges of transition, Elena Santagostino (Italy)
Case presentation of a transition, Pia Petrini (Sweden)
The case for the children’s hospital comprehensive care centre, Ri Liesner (UK)
The case for the comprehensive care centre with a children’s department, Robert Klamroth (Germany)
Discussion and debate
Summary and close, Pier Mannuccio Mannucci (Italy), Jan Astermark (Sweden)

THURSDAY, 3rd February, 2011
Registration Opening Times 07:00–18:00 (level -1 of the Hotel)
All sessions take place in the plenary room Crans-Montana, level -1 of the Hotel
07:45–09:30
Baxter Satellite Symposium
Comprehensive Inhibitor Management from Start to Finish: Predict, Prevent and Treat
07:45–07:55  Opening remarks. Armin Reininger, Baxter Healthcare
07:55–08:15  Predict: Genetics of Inhibitors. Jan Astermark, (Sweden)
08:15–08:35  Prevent: Therapies that May Prevent Inhibitor Development. Günter Auerswald (Germany)
08:35–08:55  Treat: Immune Tolerance Induction – Eradicating Inhibitors. Charles Hay (UK)
08:55–09:15  Treat: Persistent Inhibitors – Optimal Therapy towards Joint Protection. Alessandro Gringeri (Italy)
09:15–09:30  Q&A. Armin Reininger, Baxter Healthcare
THURSDAY, 3rd February

Registration Opening Times  07:00–18:00 (level -1 of the Hotel)

All sessions take place in the plenary room Crans-Montana, level -1 of the Hotel

10:00–12:30
Introduction

Session 1  
Ongoing studies  
Ph. de Moerloose  
Chairs: P.M. Mannucci, C.A. Ludlam

EUHASS
M. Makris (UK)

EAHAD working parties
J. Oldenburg, A. Federici, F. Peyvandi (Germany and Italy)

SIPPET, RESIST
A. Gringeri (Italy)

PedNet studies
K. Fischer (Netherlands)

EHTSB, ADVANCE
G. Dolan (UK)

12:30–14:00  
Lunch

14:00–15:30
Session 2  
Platelet disorders  
Chairs: I. Peake, M. Makris

Identification of new platelet phenotypes through phenotyping and targeted sequencing
S. Watson (UK)

Diagnostic assessment of macrothrombocytopenia and the place of MYH9 mutation screening
CL. Balduini (Italy)

Management of inherited thrombocytopenias
T. Lecompte (France)

15:30–16:00  
Break

16:00–17:30
Session 3  
Rare bleeding disorders  
Chairs: F. Peyvandi, J. Oldenburg

Hereditary haemorrhagic telangectasia
L.M. Botella (Spain)

Acquired von Willebrand Syndrome (AVWS)
A.B. Federici (Italy)

Does mild factor XI deficiency really cause bleeding?
U. Seligsohn (Israel)

17:30  
General Assembly

19:00  
Gala dinner at Ariana Museum
FRIDAY, 4th February

Registration Opening Times 07:30–16:00 (level -1 of the Hotel)
All sessions take place in the plenary room Crans-Montana, level -1 of the Hotel

8:00–10:00
Session 4 Haemophilic arthropathy

AROSENIEUS LECTURE: Haemophilic arthropathy.

Validation of three-dimensional gait analysis (3DGA) for the detection of infraclinical changes in hemophilic lower limb arthropathy

Debate
Ankle replacement. Yes
J. Asencio (France)
Ankle replacement. No
L. Solimeno (Italy)

10:00–10:30
Break

10:30–12:00
Session 5 Haemophilia and aging

Population demographics in haemophilia
J. Windyga (Poland)
Challenges to manage cardiovascular diseases in haemophilia
R.E. Schutgens (Netherlands)
Osteoporosis: a real problem in haemophilia?
M. Khawaji (Sweden)

12:00–13:30
Lunch

12:15–13:15
Special Lectures

Erik von Willebrand – who was he?
O. Lindberg (Finland)
von Willebrand disease: recent history, current status and future prospects
D. Lillicrap (Canada)

13:30–14:30
Session 6 Women and children with bleeding

Menorrhagia in women with bleeding disorders
F. Peyvandi (Italy)
Management of pregnancy in women with bleeding disorders
R.A. Kadir (UK)

14:30–15:30
Debate Delivery of a severe haemophilia fetus.
I. Pabinger (Austria)
Caesarean section or Vaginal delivery
R. Ljung (Sweden)

16:00
End of the Congress